Constant regulation for stable CD8 T-cell functional avidity and its possible implications for cancer immunotherapy.
Fiche du document
- doi: 10.1002/eji.202049016
- issn: 0014-2980
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1002/eji.202049016
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33704770
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1521-4141
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_DE9645D7CF3A5
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Mots-clés
CD8 T cells; TCR affinity; avidity regulation; co-receptors; functional avidity; coreceptorsSujets proches
Thymus-dependent lymphocytes Thymus-derived cells T lymphocytes Thymus-dependent cells Carcinoma Cancers Malignancy (Cancer) Malignant tumorsCiter ce document
C.B. Gilfillan et al., « Constant regulation for stable CD8 T-cell functional avidity and its possible implications for cancer immunotherapy. », Serveur académique Lausannois, ID : 10.1002/eji.202049016
Métriques
Partage / Export
Résumé
The functional avidity (FA) of cytotoxic CD8 T cells impacts strongly on their functional capabilities and correlates with protection from infection and cancer. FA depends on TCR affinity, downstream signaling strength, and TCR affinity-independent parameters of the immune synapse, such as costimulatory and inhibitory receptors. The functional impact of coreceptors on FA remains to be fully elucidated. Despite its importance, FA is infrequently assessed and incompletely understood. There is currently no consensus as to whether FA can be enhanced by optimized vaccine dose or boosting schedule. Recent findings suggest that FA is remarkably stable in vivo, possibly due to continued signaling modulation of critical receptors in the immune synapse. In this review, we provide an overview of the current knowledge and hypothesize that in vivo, codominant T cells constantly "equalize" their FA for similar function. We present a new model of constant FA regulation, and discuss practical implications for T-cell-based cancer immunotherapy.